Kezar Life Sciences, Inc., a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases, reported a net loss of $56.0 million for the year ended December 31, 2025, a decrease from a net loss of $83.7 million in 2024. The company’s accumulated deficit reached $490.5 million as of the end of 2025. Total operating expenses for the year were $59.1 million, down from $90.6 million in the previous year, primarily due to a significant reduction in research and development expenses, which fell to $33.8 million from $65.7 million. This decrease was attributed to the termination of the PALIZADE Phase 2b clinical trial and a reduction in workforce as part of a restructuring plan.
In October 2025, Kezar announced plans to explore strategic alternatives to maximize stockholder value after failing to align with the FDA on a registrational clinical trial for its lead product candidate, zetomipzomib, intended for treating autoimmune hepatitis. The company has since implemented a restructuring plan, which included a workforce reduction of approximately 70%. In March 2026, Kezar entered into an asset purchase agreement with Enodia Therapeutics SAS, transferring its Sec61-based discovery and development program assets, while retaining rights to zetomipzomib.
Kezar's research and development efforts have primarily focused on zetomipzomib, a selective immunoproteasome inhibitor. The company has completed several clinical trials, including the PORTOLA trial, which showed promising results in achieving complete biochemical response in patients with autoimmune hepatitis. However, the PALIZADE trial was terminated due to safety concerns, including serious adverse events. The company is currently awaiting further guidance from the FDA regarding the development of zetomipzomib.
Looking ahead, Kezar expects to continue incurring significant losses as it evaluates strategic alternatives and manages its operations. The company reported cash and cash equivalents of $71.9 million as of December 31, 2025, which it believes will fund its operations for at least the next 12 months. However, the company acknowledges the need for additional funding to support its ongoing development efforts and to navigate the uncertainties of the biotechnology market.
About Kezar Life Sciences, Inc.
Kezar Life Sciences is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases. Its lead candidate, zetomipzomib, targets the immunoproteasome to treat autoimmune conditions like AIH and lupus. The company aims to offer broad immunomodulation with convenient dosing, leveraging proprietary IP and strategic collaborations to address high unmet medical needs in autoimmune and inflammatory disorders.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.